• Contact us
  • E-Submission

Ewha Med J : The Ewha Medical Journal

OPEN ACCESS
mobile search button mobile menu button
Search
Advanced Search
ABOUT
BROWSE ARTICLES
JOURNAL POLICIES
FOR CONTRIBUTORS

Articles

Page Path

Review Article

ABO-Incompatible Kidney Transplantation

Shina Lee, Duk-Hee Kang
The Ewha Medical Journal 2015;38(1):7-13. Published online: March 26, 2015

Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.

Corresponding author Duk-Hee Kang. Department of Internal Medicine, Ewha Womans University School of Medicine, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul 158-710, Korea. Tel: 82-2-2650-5132, Fax: 82-2-2650-2505, dhkang@ewha.ac.kr
• Received: February 11, 2015   • Accepted: February 16, 2015

Copyright © 2015, The Ewha Medical Journal

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 46 Views
  • 0 Download
  • 2 Crossref
prev next

Full Article

Download PDF Download PDF
  • Kidney transplantation is the best treatment for end-stage renal disease patients. However, the relative shortage of organs for transplantation has led to ABO-incompatible kidney transplantation as an accepted method to expand the pool of kidney donors. Recent advances in immunosuppression and antibody removal methods have made ABO-incompatible kidney transplantation more feasible, and have increased the opportunities for patients to receive kidney transplantation, as well as for special patients with ABO-compatible donor. Indeed, the outcome of ABO-incompatible kidney transplantation has shown remarkable developments and is now comparable to that of ABO-compatible kidney transplantation during last decade. However, there are still some uncertain issues to be addressed in ABO-incompatible kidney transplantation. In this article, we reviewed the current status and protocol of ABO-incompatible kidney transplantation and listed the concerns to be addressed in near future.
  • Keywords: Blood group incompatibility; Kidney transplantation; Immunosuppression; Antibodies
This work was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science, ICT & Future Planning (2010-0019866) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (2012R1A2A2A01013541).
  • 1. Kim MS, Kim SI, Kim YS. Current status of deceased donor organ recovery and sharing in Korea. J Korean Med Assoc 2008;51:685-691.
  • 2. Korean Network for Organ Sharing2013 Annual data report [Internet] Seoul, Korean Network for Organ Sharing. 2015;cited 2015 Jan 20. Available from: http://www.konos.go.kr.
  • 3. Hume DM, Merrill JP, Miller BF, Thorn GW. Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest 1955;34:327-382.
  • 4. Alexandre GP, Squifflet JP, De Bruyere M, Latinne D, Moriau M, Ikabu N, et al. Splenectomy as a prerequisite for successful human ABO-incompatible renal transplantation. Transplant Proc 1985;17:138-143.
  • 5. Takahashi K, Tanabe K, Ooba S, Yagisawa T, Nakazawa H, Teraoka S, et al. Prophylactic use of a new immunosuppressive agent, deoxyspergualin, in patients with kidney transplantation from ABO-incompatible or preformed antibody-positive donors. Transplant Proc 1991;23(1 Pt 2):1078-1082.
  • 6. Ota K, Takahashi K, Agishi T, Sonda T, Oka T, Ueda S, et al. Multicentre trial of ABO-incompatible kidney transplantation. Japanese Biosynsorb ABO-incompatible kidney transplant study group. Transpl Int 1992;5:S40-S43.
  • 7. Ichimaru N, Takahara S. Japan's experience with living-donor kidney transplantation across ABO barriers. Nat Clin Pract Nephrol 2008;4:682-692.
  • 8. Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigenspecific immunoadsorption and rituximab. Transplantation 2003;76:730-731.
  • 9. Takahashi K, Saito K. ABO-incompatible kidney transplantation. Transplant Rev (Orlando) 2013;27:1-8.
  • 10. Montgomery JR, Berger JC, Warren DS, James NT, Montgomery RA, Segev DL. Outcomes of ABO-incompatible kidney transplantation in the United States. Transplantation 2012;93:603-609.
  • 11. Genberg H, Kumlien G, Wennberg L, Tyden G. The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation. Nephrol Dial Transplant 2011;26:2394-2400.
  • 12. Morath C, Becker LE, Leo A, Beimler J, Klein K, Seckinger J, et al. ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation 2012;93:827-834.
  • 13. Flint SM, Walker RG, Hogan C, Haeusler MN, Robertson A, Francis DM, et al. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. Am J Transplant 2011;11:1016-1024.
  • 14. Tobian AA, Shirey RS, Montgomery RA, Ness PM, King KE. The critical role of plasmapheresis in ABO-incompatible renal transplantation. Transfusion 2008;48:2453-2460.
  • 15. Vo AA, Petrozzino J, Yeung K, Sinha A, Kahwaji J, Peng A, et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation 2013;95:852-858.
  • 16. Alachkar N, Lonze BE, Zachary AA, Holechek MJ, Schillinger K, Cameron AM, et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012;94:165-171.
  • 17. Montgomery RA, Locke JE, King KE, Segev DL, Warren DS, Kraus ES, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009;87:1246-1255.
  • 18. Wahrmann M, Schiemann M, Marinova L, Kormoczi GF, Derfler K, Fehr T, et al. Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption. Nephrol Dial Transplant 2012;27:2122-2129.
  • 19. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242-251.
  • 20. Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant 2011;11:196-202.
  • 21. Chikaraishi T, Sasaki H, Tsutsumi H, Miyano S, Nakazawa R, Nakano T, et al. ABO blood type incompatible kidney transplantation without splenectomy prepared with plasma exchange and rituximab. Transplant Proc 2008;40:3445-3447.
  • 22. Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King KE, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004;4:1315-1322.
  • 23. Kohei N, Hirai T, Omoto K, Ishida H, Tanabe K. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012;12:469-476.
  • 24. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009;9:201-209.
  • 25. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008;86:1754-1761.
  • 26. Walsh RC, Everly JJ, Brailey P, Rike AH, Arend LJ, Mogilishetty G, et al. Proteasome inhibitor-based primary therapy for antibodymediated renal allograft rejection. Transplantation 2010;89:277-284.
  • 27. Wahrmann M, Haidinger M, Kormoczi GF, Weichhart T, Saemann MD, Geyeregger R, et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010;89:1385-1390.
  • 28. Guthoff M, Schmid-Horch B, Weisel KC, Haring HU, Konigsrainer A, Heyne N. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl Immunol 2012;26:171-175.
  • 29. Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009;9:231-235.
  • 30. Gonzalez-Roncero F, Suner M, Bernal G, Cabello V, Toro M, Pereira P, et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 2012;44:2690-2694.
  • 31. Noone D, Al-Matrafi J, Tinckam K, Zipfel PF, Herzenberg AM, Thorner PS, et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012;12:2546-2553.
  • 32. Stewart ZA, Collins TE, Schlueter AJ, Raife TI, Holanda DG, Nair R, et al. Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc 2012;44:3033-3036.
  • 33. Tanabe K, Tokumoto T, Ishida H, Ishikawa N, Miyamoto N, Kondo T, et al. Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid. Transplant Proc 2004;36:2175-2177.
  • 34. Geyer M, Fischer KG, Drognitz O, Walz G, Pisarski P, Wilpert J. ABO-incompatible kidney transplantation with antigen-specific immunoadsorption and rituximab: insights and uncertainties. Contrib Nephrol 2009;162:47-60.
  • 35. Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Naim M, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008;86:820-825.
  • 36. Toki D, Ishida H, Setoguchi K, Shimizu T, Omoto K, Shirakawa H, et al. Acute antibody-mediated rejection in living ABOincompatible kidney transplantation: long-term impact and risk factors. Am J Transplant 2009;9:567-577.
  • 37. Tobian AA, Shirey RS, Montgomery RA, Tisch DJ, Ness PM, King KE. Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation. Transfusion 2009;49:1248-1254.
  • 38. Lawrence C, Galliford JW, Willicombe MK, McLean AG, Lesabe M, Rowan F, et al. Antibody removal before ABO-incompatible renal transplantation: how much plasma exchange is therapeutic? Transplantation 2011;92:1129-1133.
  • 39. Chung BH, Lim JU, Kim Y, Kim JI, Moon IS, Choi BS, et al. Impact of the baseline anti-A/B antibody titer on the clinical outcome in ABO-incompatible kidney transplantation. Nephron Clin Pract 2013;124:79-88.
  • 40. Tanabe K. Interinstitutional variation in the measurement of anti-A/B antibodies: the Japanese ABO-Incompatible Transplantation Committee survey. Transplantation 2007;84:12 Suppl. S13-S16.
  • 41. Shirakawa H, Ishida H, Shimizu T, Omoto K, Iida S, Toki D, et al. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. Clin Transplant 2011;25:878-884.
  • 42. Fuchinoue S, Ishii Y, Sawada T, Murakami T, Iwadoh K, Sannomiya A, et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 2011;91:853-857.
  • 43. Toki D, Ishida H, Horita S, Setoguchi K, Yamaguchi Y, Tanabe K. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009;22:447-454.
  • 44. Kong JM, Ahn J, Park JB, Chung BH, Yang J, Kim JK, et al. ABO incompatible living donor kidney transplantation in Korea: highly uniform protocols and good medium-term outcome. Clin Transplant 2013;27:875-881.
  • 45. Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010;10:89-98.
  • 46. Kong JM, Lee DR, Jeong JH, Choi JH, Lee JH, Lee WR, et al. ABO blood group incompatible living donor kidney transplantation without splenectomy. J Korean Soc Transplant 2009;23:71-76.
  • 47. Yu H, Kim YJ, Kwon SW, Han DJ, Park JB, Park JS, et al. ABO incompatible living donor kidney transplantation with rituximab and plasmapheresis: a single center experience. Korean J Nephrol 2011;30:386-393.
  • 48. Chang CL, Jeong JH, Kim JP, Lee DR, Kong JM, Kim BC. A single center experience of ABO incompatible kidney transplantation. J Korean Soc Transplant 2012;26:261-268.
Fig. 1

Strategy for immunosuppressive therapy in ABO-incompatible kidney transplantation. It is important to implement B cell-mediated immunosuppression and T cell-mediated immunosuppression at different times; MMF, Mycophenolate mofetil; IVIG, Intravenous immunoglobulin.

emj-38-7-g001.jpg

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Formulation of the Scope and Key Questions of the Guideline Recommendations for Immunosuppressive Treatment in Kidney Transplantation
      Seungyeon Huh, Nayoung Han, Minji Sohn, Junghwa Ryu, Jaeseok Yang, Jung Mi Oh
      Korean Journal of Clinical Pharmacy.2019; 29(1): 18.     CrossRef
    • Comparative Analysis of Effectiveness and Safety between High and Low Dose Rituximab in ABO-Incompatible Kidney Transplant Recipients
      문정은, 김재송, 손은선, 김효진
      Journal of Korean Society of Health-System Pharmacists.2017; 34(2): 200.     CrossRef

    Download Citation

    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

    Format:

    Include:

    ABO-Incompatible Kidney Transplantation
    Ewha Med J. 2015;38(1):7-13.   Published online March 26, 2015
    DOI: https://doi.org/10.12771/emj.2015.38.1.7
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    ABO-Incompatible Kidney Transplantation
    Ewha Med J. 2015;38(1):7-13.   Published online March 26, 2015
    DOI: https://doi.org/10.12771/emj.2015.38.1.7
    Close

    Figure

    • 0
    ABO-Incompatible Kidney Transplantation
    Image
    Fig. 1 Strategy for immunosuppressive therapy in ABO-incompatible kidney transplantation. It is important to implement B cell-mediated immunosuppression and T cell-mediated immunosuppression at different times; MMF, Mycophenolate mofetil; IVIG, Intravenous immunoglobulin.

    Fig. 1

    ABO-Incompatible Kidney Transplantation
    Ewha Med J : The Ewha Medical Journal

    ABOUT

    BROWSE ARTICLES 

    JOURNAL POLICIES

    FOR CONTRIBUTORS 

    © Ewha Womans University College of Medicine.
    TOP